Cite

HARVARD Citation

    Cohen, M. et al. (n.d.). The "Dual‐Pathway" Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2‐TIMI 51 Trial. Cardiovascular therapeutics. 32 (5), pp. 224-232. [Online]. 
  
Back to record